*Optimal dilutions/concentrations should be determined by the researcher.
|1:500 - 1:1000
|1:50 - 1:100
Not tested in other applications.
Mouse, Rat(>80% identity)
PBS (without Mg²⁺ and Ca²⁺) pH7.4, 150mM NaCl, 50% Glycerol
0.02% Sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Batch dependent (Please refer to the vial label for the specific concentration.)
The antiserum was produced against synthesized phosphopeptide derived from human MEK2 around the phosphorylation site of threonine 394 (P-G-Tp-P-T).
Purified by sequential chromatography on phospho- and non-phospho-peptide affinity columns.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
CFC4,MAP2K2,MAPKK2,MEK2,MKK2,PRKMK2,mitogenactivated protein kinase kinase 2,mitogen-activated protein kinase kinase 2
The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]